Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Prostate cancer treatment guidelines recommend against aggressive therapy for those with a life expectancy of less than 10 years.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

Discover a study where findings suggest that testosterone therapy can be safely administered to carefully selected men ...

The findings, published in the Journal of Clinical Oncology, show that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements, significantly reduced the growth rate ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

Incorporating biomarkers into standard practice enhances diagnostic accuracy, supporting confident treatment decisions and optimizing care.

In this systematic review, ten studies reported risk reclassification of prostate cancer with genome classifier testing, with ...